- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03694717
Time Course Evolution of Cardiac Output (TCCO)
Time Course Evolution of Cardiac Output in Critically Ill Patients After a Fluid Expansion
Fluid expansion is the first therapeutic option in patients presenting acute circulatory failure but the duration of its hemodynamic effects (persistency and time of maximal increase in cardiac output) is unknown.
This study is seeking to describe in critically ill patients, the time course evolution of cardiac output over a 2-hours period after a fluid expansion.
The objectives are:
- to identify patterns of fluid responsiveness
- to determine the time when the maximal increase in cardiac output occurs during and a after fluid expansion
- to compare patients' characteristics between patterns
Patients with acute circulatory failure will be recruited as soon as a fluid expansion will be decided by the physician in charge and the effects of fluid expansion on hemodynamic indices (cardiac output, arterial pressure) will be continuously recorded through a transpulmonary thermodilution device over a 2-hours period.
No changes in ventilatory settings nor vasopressors or sedatives will be allowed during the study.
Patients will be categorized into patterns according to the changes in cardiac output after fluid expansion and their characteristics will be compared.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study will be conducted in four medico-surgical ICUs in France between April 2016 and April 2018.
Since fluid challenge and invasive monitoring by thermodilution device is standard of care for septic shock management, the institutional review board waived patient consent. All patients and/or their next of kind will receive written information.
Eligible patients will have to present an acute circulatory failure for whom the physician in charge will decide to start a fluid expansion.
Hemodynamic variables will be obtained through transpulmonary thermodilution and pulse contour analysis (PICCO2 device, Pulsion Germany).
Fluid expansion will consist in the infusion of 500 ml of saline through a central venous catheter in a standardized 10-minutes period. The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
Fluid responsiveness will be defined by an increase in cardiac output over 15-per-cent from baseline (before fluid expansion).
Study design:
At time of decision to make the fluid expansion, a calibration of the PICCO2 device will be performed and a first set of hemodynamic measurements will be collected (cardiac output, cardiac function index, extravascular lung water, permeability vascular pulmonary index, global end diastolic volume, arterial pressure, heart rate).
Then, fluid expansion will be administrated in less than 10 minutes. From the start of fluid expansion to the end of the two-hours period ot time, pulse contour cardiac output and arterial pressure will be continuously recorded.
During the whole two hours period, no change in vasopressor dosage nor mechanical ventilation settings will be allowed.
In case of hemodynamic instability, defined by a mean arterial pressure under 65mmHg, a new fluid expansion could be realized. In this last case, the protocol will start again from the beginning.
Type d'étude
Inscription (Réel)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- acute circulatory failure (infusion of norepinephrine)
- invasive mechanical ventilation through an endotracheal tube
- decision of fluid expansion
Non inclusion Criteria:
- extracorporeal membranous oxygenation (ECMO)
- active bleeding
- continuous renal replacement therapy with weight loss
- administration of diuretics within the past six hours
- decision of therapeutic limitation,
- age under eighteen years
Exclusion criteria:
- hemodynamic instability after fluid expansion (mean arterial pressure < 65mmHg)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cohorte
- Perspectives temporelles: Éventuel
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Patients
The patients will receive a 500 ml fluid expansion over a standardized 10 minutes period
|
The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular).
The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in cardiac output during fluid expansion
Délai: 10 minutes
|
Difference between maximal cardiac output during fluid expansion and baseline
|
10 minutes
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in cardiac output after fluid expansion
Délai: 2 hours
|
Change in cardiac output after fluid expansion
|
2 hours
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Martin Dres, MD, PhD, APHP
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ADOREPS
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Saline Solution for Injection
-
Cidara Therapeutics Inc.Janssen PharmaceuticalsActif, ne recrute pasEn bonne santéÉtats-Unis
-
Jeffrey Alan Klein, MDPas encore de recrutementAnesthésie locale | Irritation au site d'injection | Inconfort au site d'injection | Ecchymoses au site d'injection | Effet indésirable de l'acide benzoïqueÉtats-Unis
-
Cidara Therapeutics Inc.Janssen PharmaceuticalsComplétéEn bonne santéÉtats-Unis
-
Jianersheng (Zhuhai) Pharmaceutical Technology...RecrutementLe cadmium dépasse la normeChine
-
Jianersheng (Zhuhai) Pharmaceutical Technology...ComplétéExposition au cadmiumChine
-
Mayo ClinicRetiré
-
Marval Pharma Ltd.RésiliéVolontaires en bonne santéÉtats-Unis
-
Seoul St. Mary's HospitalComplétéRhinite atrophiqueCorée, République de
-
University of California, DavisEunice Kennedy Shriver National Institute of Child Health and Human Development...ComplétéAcidocétose diabétique | Œdème cérébralÉtats-Unis
-
Wright State UniversityBayerRésilié